The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment

BACKGROUND: EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or prognostic value has not been clarified. METHODS: Patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sueoka‐Aragane, Naoko, Nakashima, Chiho, Yoshida, Hironori, Matsumoto, Naohisa, Iwanaga, Kentaro, Ebi, Noriyuki, Nishiyama, Akihiro, Yatera, Kazuhiro, Kuyama, Shoichi, Fukuda, Minoru, Ushijima, Sunao, Umeguchi, Hitomi, Harada, Daijiro, Kashiwabara, Kosuke, Suetsugu, Takayuki, Fujimoto, Nobukazu, Tanaka, Fumihiro, Uramoto, Hidetaka, Yoshii, Chiharu, Nakatomi, Katsumi, Koh, Genju, Seki, Nobuhiko, Aoe, Keisuke, Nosaki, Kaname, Inoue, Koji, Takamori, Ayako, Kawaguchi, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209625/
https://www.ncbi.nlm.nih.gov/pubmed/33982444
http://dx.doi.org/10.1002/cam4.3929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209625/
https://www.ncbi.nlm.nih.gov/pubmed/33982444
http://dx.doi.org/10.1002/cam4.3929

Ejemplares similares